{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority was tested by comparing the upper limit of the 95% confidence interval for the hazard ratio to the non-inferiority margin of 1.25","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","pValue":"0.071","pValueComment":"For difference between arms, \\< 0.001 for non-inferiority","paramType":"Hazard Ratio (HR)","paramValue":"0.84","statisticalMethod":"Wald Chi-Square Test","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"804"},{"groupId":"OG001","value":"756"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1004"},{"groupId":"OG001","value":"983"}],"units":"Participants"}],"description":"Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).","groups":[{"description":"Participants received capecitabine 1250 (mg/m \\^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).","id":"OG000","title":"Capecitabine"},{"description":"Participants received leucovorin 20 mg/m \\^ 2 followed by 5-fluorouracil at 425 mg/m \\^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).","id":"OG001","title":"5-Fluorouracil + Leucovorin"}],"paramType":"NUMBER","populationDescription":"All randomized population included all participants who were randomized to one of the two treatment arms, regardless of whether they received any study medication.","reportingStatus":"POSTED","timeFrame":"Approximately 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}